Genis is an innovative Icelandic biotechnology company, pioneering the development of therapeutic chitin derivatives.

Our goal is to address an unmet need by providing effective therapeutic solutions across a number of inflammatory diseases, including lung diseases such as asthma and COPD, type II diabetes, rheumatoid arthritis and endometriosis.

We are also developing a number of orthobiologic applications that are based on the regenerative tissue and osteogenic activities and anti-bacterial properties of chitin derivatives.

Our drug development program is a result of extensive research on short chain chitin derivatives and its therapeutic potential over a number of years.

We have developed proprietary short chain chitosan molecules that target members of the chitinase-like protein (CLP) family. Mammalian chitinases and the CLPs have been shown to be involved in inflammation and formation of scar tissue. By targeting the CLPs, we have developed a therapeutic strategy that combats inflammation and stimulates natural tissue regeneration.